News: Plethora Solutions Holding Plc (PLE.L)

PLE.L on London Stock Exchange

16.50GBp
3:00am EST
Price Change (% chg)

0.00p (+0.00%)
Prev Close
16.50p
Open
16.50p
Day's High
16.50p
Day's Low
16.50p
Volume
0
Avg. Vol
16,919
52-wk High
35.98p
52-wk Low
14.00p

view news for:
Select another date:

Mon, Nov 30 2009

STOCKS NEWS EUROPE-FTSE small caps close down 0.6 pct

The FTSE Small Cap index closes 0.6 percent lower, while the blue chips are off 1.1 percent, and the midcaps end the session shedding 1.3 percent.

Continue Reading

STOCKS NEWS EUROPE-Plethora Solution up on licence win

Shares in Plethora Solutions Holdings Plc climb 9.5 percent after the British urology specialist wins the UK licence to market Dianatal Obstetric Gel, which eases childbirth by reducing friction in the birth canal.

UK Stocks -- Factors to watch on Monday

LONDON, Sept 14 (Reuters) - Britain's FTSE 100 index is seen opening 33-39 points, or as much as 0.6 percent, lower on Monday, according to financial bookmakers, tracking falls in Asia and on Wall Street, with weaker commodity prices seen denting heavyweight oils and miners.

UK Stocks -- Factors to watch on June 25

LONDON, June 25 (Reuters) - Britain's FTSE 100 index is seen opening 3-15 points lower on Thursday, according to financial bookmakers, retreating following a mixed performance on Wall Street after Federal Reserve comments failed to excite.

STOCKS NEWS UK SMALL-Holidaybreak up as trading reassures

STOCKS NEWS Reuters Results diary

STOCKS NEWS UK SMALL-Intercytex up on reports of Pfizer interest

STOCKS NEWS Reuters Results diary

Plethora sells lead drug rights

(Reuters) - Urology specialist Plethora Solutions Holdings said on Tuesday it had reduced its debt by over 90 percent as it received $8.4 million (5.3 million pounds) more for the global rights for its premature ejaculation drug from Sciele Pharma.

STOCKS NEWS UK SMALL-Albemarle & Bond up on positive trading

STOCKS NEWS Reuters Results diary

UPDATE 1-Plethora sells lead drug rights, cuts debt by 90 pct

* Says Sciele Pharma to pay extra $8.4 mln for drug rights

STOCKS NEWS EUROPE-Plethora Solutions up on PSD502 license

Shares in Plethora Solutions rise 5.5 percent as the company says it has licensed PSD502 -- a premature ejaculation drug -- for the rest of the world to its existing U.S. licensee, Sciele Pharma, for an upfront payment and royalties, and it has divested its U.S. sales and marketing operation, Timm Medical Technologies Inc.

Select another date:

Market Views

» More PLE.L Market Views

Press Releases

view news for: